| scholarly article | Q13442814 |
| P2093 | author name string | Carlos S Moreno | |
| P2860 | cites work | OTSSP167 Abrogates Mitotic Checkpoint through Inhibiting Multiple Mitotic Kinases | Q27313731 |
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications | Q27860709 | ||
| Multi-kinase inhibitor C1 triggers mitotic catastrophe of glioma stem cells mainly through MELK kinase inhibition | Q28537936 | ||
| Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms | Q33244907 | ||
| MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells. | Q33762222 | ||
| EZH2 protects glioma stem cells from radiation-induced cell death in a MELK/FOXM1-dependent manner | Q35075212 | ||
| Maternal embryonic leucine zipper kinase (MELK) reduces replication stress in glioblastoma cells | Q37099799 | ||
| Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer | Q37389790 | ||
| The Evolving Landscape of HER2 Targeting in Breast Cancer | Q38552750 | ||
| Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. | Q39837918 | ||
| A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments | Q42492946 | ||
| Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment | Q46641346 | ||
| Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer. | Q55008828 | ||
| P433 | issue | 10 | |
| P921 | main subject | biomarker | Q864574 |
| P304 | page(s) | E1367-E1368 | |
| P577 | publication date | 2016-10-01 | |
| P1433 | published in | Journal of thoracic disease | Q26841814 |
| P1476 | title | MELK kinase holds promise as a new radiosensitizing target and biomarker in triple-negative breast cancer | |
| P478 | volume | 8 |
| Q91586857 | Bioinformatic analysis identifies potentially key differentially expressed genes in oncogenesis and progression of clear cell renal cell carcinoma |
| Q92465189 | Mutant P53 induces MELK expression by release of wild-type P53-dependent suppression of FOXM1 |
| Q94475380 | Narrowing the focus: Therapeutic cell surface targets for refractory triple-negative breast cancer |
| Q46233466 | The microRNAs miR-200b-3p and miR-429-5p target the LIMK1/CFL1 pathway to inhibit growth and motility of breast cancer cells. |
| Q47801891 | Whole-exome analysis of a Li-Fraumeni family trio with a novel TP53 PRD mutation and anticipation profile. |
Search more.